{"product_id":"molavir-molnupiravir-200mg","title":"Molavir (Molnupiravir) 200mg","description":"\u003ch1\u003eMolavir (Molnupiravir)200mg\u003c\/h1\u003e\r\n\u003ch3\u003eDosage Forms : Capsule\u003c\/h3\u003e\r\n\u003ch3\u003eStrengths: 200mg\u003c\/h3\u003e\r\n\u003ch3\u003eCOVID-19 Disease Treatment\u003c\/h3\u003e\r\nTreatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and who are at high risk for progression to severe COVID-19, including hospitalization or death\r\n\r\n800 mg PO q12hr for 5 days.\r\n\r\nInitiate as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset\r\n\r\nCompleting the full 5-day treatment course and continuing to isolate in accordance with public health recommendations are important to maximize viral clearance and minimize viral transmission\r\n\r\nIf patient is hospitalized due to severe or critical COVID-19 after starting treatment with Molnupiravir, completion of the full 5-day treatment is at the healthcare provider’s discretion\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eRenal impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild or moderate (eGFR \u0026gt;30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eSevere (eGFR \u0026lt;30 mL\/min), end-stage renal disease, or patients on dialysis: Pharmacokinetics not evaluated; not expected to have a significant effect on NHC (N4-hydroxycytidine) exposure\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild to severe (Child-Pugh Class A to C): No dosage adjustment required\u003c\/li\u003e\r\n \t\u003cli\u003ePreclinical data indicate that hepatic elimination is not expected to be a major route of NHC elimination\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\r\nVerify pregnancy status in females of childbearing potential before initiating\r\n\u003ch4\u003eLimitations of use\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eNot authorized for use in patients aged \u0026lt;18 years\u003c\/li\u003e\r\n \t\u003cli\u003eNot authorized for initiation of treatment in patients requiring hospitalization owing to COVID-19\u003c\/li\u003e\r\n \t\u003cli\u003eNot authorized for use for \u0026gt;5 consecutive days\u003c\/li\u003e\r\n \t\u003cli\u003eNot authorized for preexposure or postexposure prophylaxis for prevention of COVID-19.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eAdverse Effects\u003c\/h2\u003e\r\n\u003cdiv class=\"refsection_content\"\u003e\r\n\u003ch3\u003e1-10%\u003c\/h3\u003e\r\nDiarrhea (2%)\r\n\r\nNausea (1%)\r\n\r\nDizziness (1%)\r\n\u003ch4\u003e≤2%\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eSelected Grade 3 and 4 laboratory abnormalities in chemistry (ALT, AST, creatinine, and lipase) and hematology (hemoglobin, platelets, and leukocytes)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eRequired reporting for serious adverse events and medication errors\u003c\/h3\u003e\r\nPrescribers and\/or the provider’s designee are\/is responsible for mandatory reporting of all serious adverse events and medication errors potentially drug-related within 7 calendar days from the onset of the event\r\n\u003ch4\u003eSerious adverse events are defined as\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDeath or a life-threatening adverse event;\u003c\/li\u003e\r\n \t\u003cli\u003eA medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly;\u003c\/li\u003e\r\n \t\u003cli\u003eInpatient hospitalization or prolongation of existing hospitalization;\u003c\/li\u003e\r\n \t\u003cli\u003eA persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or\u003c\/li\u003e\r\n \t\u003cli\u003eA congenital anomaly\/birth defect\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eCautions\u003c\/h3\u003e\r\nThere are limited clinical data available; serious and unexpected adverse events may occur that have yet to be reported\r\n\r\nMay cause fetal harm when administered to pregnant females\r\n\u003ch4\u003eBone and cartilage toxicity\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eNot authorized for use in patients aged \u0026lt;18 years owing to possible effects on bone and cartilage growth\u003c\/li\u003e\r\n \t\u003cli\u003eBone and cartilage toxicity was observed in rats after repeated dosing\u003c\/li\u003e\r\n \t\u003cli\u003eSafety and efficacy have not been established in pediatric patients\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eMissed dose\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;10 hours: Take missed dose as soon as possible, and resume normal dosing schedule\u003c\/li\u003e\r\n \t\u003cli\u003e\u0026gt;10 hours: Skip dose, and take the next dose at the regularly scheduled time\u003c\/li\u003e\r\n \t\u003cli\u003eDo not double dose to make up for missed dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eStorage\u003c\/h3\u003e\r\nStore at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)\r\n\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948395563,"sku":"RL142023090150","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655871446-12d98b4e23800d9.png?v=1787022115","url":"https:\/\/xomeds.com\/products\/molavir-molnupiravir-200mg","provider":"XOMEDS","version":"1.0","type":"link"}